

$\frac{1}{n} \sum_{i=1}^n x_i = \bar{x}$

50

50

50

50

10

20

30

40

50

[illegible]

50

50

[illegible]

50

50

20

40

50

-

10

[illegible]

20

30

40

50

50

50

μ

$\frac{1}{\text{m}^2 \cdot \text{s}} = \frac{\text{kg}}{\text{m}^2 \cdot \text{s}}$

[illegible][illegible]

μ

10

20

30

40

50

50

50

$$\frac{1}{\sqrt{\pi}} \int_{-\infty}^{\infty} e^{-x^2} dx = 1$$

50

50

10

選抜した抗HLA-DRモノクローナル抗体の性質

20

30

40

50

[illegible]

10

20

30

40

50

[illegible]

[illegible]

□ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □
 <HD4 重鎖可変領域> (配列番号 1 6)

GTCGACCCAGCCCTGGGATTTTCAGGTGTTTTCAGGTGTTTTCATTTGGTGATCAGGACTGAACAGAGAGA
 ACTCACCATGGAGTTTGGGCTGAGCTGGCTTTTTCTTGTGGCTATTTTAAAAGGTGTCCAGTGTGAGGTGCA
 ACTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATT
 CACCTTTAGCAGCTATGCCATGACCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGGTAT
 TAGTGGTGGTGGTGATAGCACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTC
 CAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAGAGA
 TCATGGTTCGGGGAGTTATTATCCCTACTGGTTTACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTC
 AGCTAGC

10

<HD4 重鎖可変領域> (配列番号 1 7)

MEFGLSWLFLVAILKGVQCEVQLLES GGGLVQPGGSLRLSCAASGFTFSSYAMTWVRQAPGKLEWVSGISG
 GGDSTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARDHGS GSYPYWFWDYWGQGLVTVSSA

20

<HD4 軽鎖可変領域> (配列番号 1 8)

AGATCTGCTGCTCAGTTAGGACCCAGAGGGAACCAATGGAAACCCAGCGCAGCTTCTCTTCCTCCTGCTACT
 CTGGCTCCCAGATACCACCGGAGAACTTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGA
 AAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCCGCTACTTAGCCTGGTACCAGCAGAAACC
 TGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCA GTGG
 CAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTG
 TCAGCAGTATGGTAGCTCACCGCTCACTTTCCGGCGGAGGGACCAAGGTGGAGATCAAACGTACG

30

<HD4 軽鎖可変領域> (配列番号 1 9)

METPAQLLFLLLLWLPD TTGELVL TQSPGTL SLSPGERATLSCRASQSVSSRYLAWYQQKPGQAPRLLIYGA
 SSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQYGS SPLTFGGGTKEIKRT

40

□ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ ' □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □
 □ ' □ □ □ □ □ □ □ □ □ □
 □
 □
 □
 □
 □
 □
 □
 □

50

10

20

30

40

50

10

合成DNAの塩基配列

20

30

40

50

表 3 組換え型ベクター及び產生される組換え抗体の名称

抗体	ペクター名称	サブクラス	組換え抗体の名称	ADCC 活性	CDC 活性
HD4	N5KG1-Val Lark	IgG1	HD4G1	+	+
HD4	N5KG2Ser	IgG2Ser	HD4G2Ser	-	-
HD4	N5KG4 Lark	IgG4	HD4G4	-	-
HD8	N5KG1-Val Lark	IgG1	HD8G1	+	+
HD8	N5KG1Ser	IgG1Ser	HD8G1Ser	+	-
HD8	N5KG2	IgG2	HD8G2	-	+
HD8	N5KG2Ser	IgG2Ser	HD8G2Ser	-	-
HD8	N5KG4 Lark	IgG4	HD8G4	-	-

[illegible]

20

30

40

50

30

SEQUENCE LISTING

<110> KIRIN BEER KABUSHIKI KAISHA

<120> Anti HLA-DR antibody

<130> PH-1646-PCT

10

<140>

<141>

<150>JP2001/317054

<151>2001-10-15

20

<160> 147

<170> PatentIn Ver. 2.1

<210> 1

30

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

40

<400> 1

ccggaattcc caccatggcc ataagtgagg tccctgtg

38

<210> 2

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

10

<400> 2

aaagcggccg ctcattacag aggccccctg cgttctgc

38

<210> 3

20

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

30

<400> 3

ccggaattcc tggtcctgtc ctgttctcca gca

33

<210> 4

<211> 38

40

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 4

aaagcggccg ctcatcagct caggaatcct gttggctg

38

10

<210> 5

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

20

<223> Description of Artificial Sequence:primer

<400> 5

ggtcgggag atcatgaggg tgcctt

27

30

<210> 6

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

40

<400> 6

gtgcacgccg ctggtcaggg cgcctg

26

<210> 7

<211> 23

<212> DNA

<213> Artificial Sequence

10

<220>

<223> Description of Artificial Sequence:primer

<400> 7

ggtgccaggg ggaagaccga tgg

23

20

<210> 8

<211> 37

<212> DNA

<213> Artificial Sequence

30

<220>

<223> Description of Artificial Sequence:primer

<400> 8

atatgtcgac ccagccctgg gattttcagg tgttttc

37

40

<210> 9

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 9

10

atatgtcgac tggctgacca gggcagtcac cagag

35

<210> 10

<211> 31

<212> DNA

20

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 10

gatgggccct tggctgctagc tgaggagacg g

31

30

<210> 11

<211> 26

<212> DNA

<213> Artificial Sequence

40

<220>

<223> Description of Artificial Sequence:primer

<400> 11

gttgaagetc ttgtgacgg gcgagc

26

<210> 12

<211> 26

<212> DNA

10

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 12

tggcgggaag atgaagacag atgggtg

26

20

<210> 13

<211> 38

<212> DNA

<213> Artificial Sequence

30

<220>

<223> Description of Artificial Sequence:primer

<400> 13

atatagatct gctgctcagt taggacccag agggaacc

38

40

<210> 14

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

10

<400> 14

atatagatct gggagtcaga ccactcagg acacagc

37

<210> 15

20

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

30

<400> 15

aagacagatg gtgcagccac cgtacgtttg at

32

<210> 16

<211> 510

40

<212> DNA

<213> Homo sapiens

<400> 16

gtcgacccag cctgggati ttcaggigt ttcaggigt ttcatttggg gatcaggact 60
 gaacagagag aactcaccat ggagtttggg ctgagctggc tttttcttgt ggctatttta 120
 aaaggigtcc agtgtgaggi gcaacigtg gagtctgggg gaggttggg acagccctggg 180
 gggctccctga gactctcctg tgcagcctct ggattcacct ttagcagcta tgccatgacc 240
 tgggtccgcc aggctccagg gaaggggctg gagtgggtct caggtattag tgggtgggtgt 300
 gatagcacat actacgcaga ctccgtgaag ggccgggtca ccatctccag agacaattcc 360
 aagaacacgc tglatctgca aatgaacagc ctgagagccg aggacacggc cgtatattac 420
 tgtgcgagag atcatgggtc ggggagttat tatecctact ggtttgacta ctggggccag 480
 ggaaccctgg tcaccgtctc ctcagctagc 510

10

<210> 17

20

<211> 143

<212> PRT

<213> Homo sapiens

<400> 17

Met Glu Phe Gly Leu Ser Trp Leu Phe Leu Val Ala Ile Leu Lys Gly

1 5 10 15

30

Val Gln Cys Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln

20 25 30

Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe

35 40 45

40

Ser Ser Tyr Ala Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu

50 55 60

Glu Trp Val Ser Gly Ile Ser Gly Gly Gly Asp Ser Thr Tyr Tyr Ala

65

70

75

80

Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn

85

90

95

Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val

10

100

105

110

Tyr Tyr Cys Ala Arg Asp His Gly Ser Gly Ser Tyr Tyr Pro Tyr Trp

115

120

125

Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala

20

130

135

140

<210> 18

<211> 424

<212> DNA

<213> Homo sapiens

30

<400> 18

agatctgctg ctcagttagg acccagaggg aaccatggaa accccagcgc agcttctctt 60

cctcctgcia ctcctggetcc cagataccac cggagaactt gtgttgacgc agtctccagg 120

cacctgtct tigtctccag gggaaagagc caccctctcc tgcagggcca gtcagagtgt 180

tagcagccgc tacttagcct ggtaccagca gaaacctggc caggctccca ggcctctcat 240

40

ctatgggtgca tccagcaggg ccactggcat cccagacagg ttcagtggca gtgggtctgg 300

gacagacttc actctcacca tcagcagact ggagcctgaa gattttgcag tgtattactg 360

tcagcaglat ggtagctcac cgctcacitt cggcggaggg accaaggtgg agatcaaacg 420
tacg 424

<210> 19

<211> 130

<212> PRT

10

<213> Homo sapiens

<400> 19

Met Glu Thr Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro

1 5 10 15

20

Asp Thr Thr Gly Glu Leu Val Leu Thr Gln Ser Pro Gly Thr Leu Ser

20 25 30

Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser

35 40 45

Val Ser Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala

50 55 60

30

Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro

65 70 75 80

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile

85 90 95

40

Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr

100

105

110

Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

115

120

125

Arg Thr

130

10

<210> 20

<211> 502

<212> DNA

<213> Homo sapiens

20

<400> 20

gtegactggc tgaccagggc agtcaccaga gctccagaca atgtctgtct ccttctcat 60
 ctctctgccc gtgctgggcc tcccatgggg tgctctgtca caggttcagc tgcagcactc 120
 aggtccagga ctgggtgaagc cctcgcagac cctctcactc acctgtgcca tctcggggga 180
 cagtgtctct agcaacagtg ctctcttgaa ctggatcagg cagtccecat cgaggggcct 240
 tgagtggtct ggaaggacat actacaggtc caagtggat aatgattatg cagtatctgt 300
 gaaaagtcga atagtcatca acccagacac atccaagaac cagttctccc tgcagctgaa 360
 ctctgtgact cccgaggaca cggctgtgta ttactgtgcg agagaaaatt tctatgggtc 420
 ggagacttgt cataagaagt attactgcta cggtatggac gtcgggggcc aagggaccac 480
 ggtcaccgtc tctcagcia gc 502

30

40

<210> 21

<211> 154

<212> PRT

<213> Homo sapiens

<400> 21

Met Ser Val Ser Phe Leu Ile Phe Leu Pro Val Leu Gly Leu Pro Trp

1 5 10 15

Gly Val Leu Ser Gln Val Gln Leu Gln His Ser Gly Pro Gly Leu Val

20 25 30

10

Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser

35 40 45

Val Ser Ser Asn Ser Ala Ser Trp Asn Trp Ile Arg Gln Ser Pro Ser

50 55 60

20

Arg Gly Leu Glu Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr

65 70 75 80

Asn Asp Tyr Ala Val Ser Val Lys Ser Arg Ile Val Ile Asn Pro Asp

85 90 95

30

Thr Ser Lys Asn Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu

100 105 110

Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Asn Phe Tyr Gly Ser Glu

115 120 125

40

Thr Cys His Lys Lys Tyr Tyr Cys Tyr Gly Met Asp Val Trp Gly Gln

130 135 140

Gly Thr Thr Val Thr Val Ser Ser Ala Ser

145

150

<210> 22

<211> 426

<212> DNA

10

<213> Homo sapiens

<400> 22

agaatctggga gtcagacca ctcaggacac agcatggaca tgagggtccc cgctcagctc 60
ctggggcttc tgcctgctctg gctcccaggt gccagatgtg ccatccagtt gacccagctc 120
ccatcctccc tgtctgcac tctaggagac agagtcacca tcaattgccg ggcaagtcag 180
ggcattagca gtgcttttagc ctggtatcag cagaaaccag ggaaagctcc taaactcctg 240
atctatgatg cctccagttt ggaaagtggg gtcccatcaa gggtcagcgg cagtgatct 300
gggacagatt tcaactctac catcagcagc ctgcagcctg aagattttgc aacttattac 360
tgtcaacagt ttaatatgtt cccgctcact ttcggcggag ggaccaaggt ggagatcaaa 420
cgtacg 426

20

30

<210> 23

<211> 132

<212> PRT

<213> Homo sapiens

<400> 23

40

Met Asp Met Arg Val Pro Ala Gln Leu Leu Gly Leu Leu Leu Trp

1

5

10

15

Leu Pro Gly Ala Arg Cys Ala Ile Gln Leu Thr Gln Ser Pro Ser Ser

20

25

30

Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser

35

40

45

Gln Gly Ile Ser Ser Ala Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys

10

50

55

60

Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val

65

70

75

80

Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr

20

85

90

95

Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln

100

105

110

Phe Asn Ser Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile

30

115

120

125

Lys Arg Thr Val

130

40

<210> 24

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

<400> 24

Trp Asn Ser Gln Lys Asp Phe Leu Glu Asp Arg Arg Ala

1

5

10

10

<210> 25

<211> 13

<212> PRT

<213> Artificial Sequence

20

<220>

<223> Description of Artificial Sequence:peptide

<400> 25

Trp Asn Ser Gln Lys Asp Phe Leu Glu Arg Arg Arg Ala

1

5

10

30

<210> 26

<211> 13

<212> PRT

<213> Artificial Sequence

40

<220>

<223> Description of Artificial Sequence:peptide

<400> 26

Trp Asn Ser Gln Lys Asp Phe Leu Glu Asp Glu Arg Ala

1

5

10

10

<210> 27

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

20

<223> Description of Artificial Sequence:peptide

<400> 27

Trp Asn Ser Gln Lys Asp Phe Leu Glu Gln Ala Arg Ala

1

5

10

30

<210> 28

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

40

<223> Description of Artificial Sequence:peptide

<400> 28

Trp Asn Ser Gln Lys Asp Ile Leu Glu Asp Glu Arg Ala

1

5

10

<210> 29

<211> 13

<212> PRT

<213> Artificial Sequence

10

<220>

<223> Description of Artificial Sequence:peptide

<400> 29

20

Trp Asn Ser Gln Lys Asp Ile Leu Glu Gln Lys Arg Gly

1

5

10

<210> 30

<211> 13

<212> PRT

<213> Artificial Sequence

30

<220>

<223> Description of Artificial Sequence:peptide

40

<400> 30

Trp Asn Ser Gln Lys Asp Ile Leu Glu Asp Arg Arg Ala

1

5

10

<210> 31

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

10

<400> 31

Trp Asn Ser Gln Lys Asp Ile Leu Glu Asp Arg Arg Gly

1

5

10

20

<210> 32

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

30

<400> 32

Trp Asn Ser Gln Lys Asp Ile Leu Glu Asp Lys Arg Ala

1

5

10

40

<210> 33

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

<400> 33

10

Trp Asn Ser Gln Lys Asp Ile Leu Glu Gln Ala Arg Ala

1

5

10

<210> 34

<211> 13

20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

30

<400> 34

Trp Asn Ser Gln Lys Asp Leu Leu Glu Gln Arg Arg Ala

1

5

10

<210> 35

40

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

<400> 35

Trp Asn Ser Gln Lys Asp Leu Leu Glu Gln Ala Arg Ala

1

5

10

10

<210> 36

<211> 13

<212> PRT

<213> Artificial Sequence

20

<220>

<223> Description of Artificial Sequence:peptide

<400> 36

Trp Asn Ser Gln Lys Asp Leu Leu Glu Gln Lys Arg Gly

1

5

10

30

<210> 37

<211> 13

<212> PRT

<213> Artificial Sequence

40

<220>

<223> Description of Artificial Sequence:peptide

<400> 37

Trp Asn Ser Gln Lys Asp Leu Leu Glu Asp Arg Arg Ala

1

5

10

<210> 38

10

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

20

<400> 38

Trp Asn Ser Gln Lys Asp Leu Leu Glu Arg Arg Arg Ala

1

5

10

<210> 39

30

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

40

<400> 39

Trp Asn Ser Gln Lys Asp Leu Leu Glu Asp Glu Arg Ala

1

5

10

<210> 40

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

10

<400> 40

Trp Asn Ser Gln Lys Asp Ala Leu Glu Gln Arg Arg Ala

1

5

10

20

<210> 41

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

30

<223> Description of Artificial Sequence:peptide

<400> 41

Trp Asn Ser Gln Lys Asp Leu Leu Glu Ala Arg Arg Ala

1

5

10

40

<210> 42

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

10

<400> 42

Trp Asn Ser Gln Lys Asp Leu Leu Glu Gln Ala Arg Ala

1

5

10

<210> 43

20

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

30

<400> 43

Trp Asn Ser Gln Lys Asp Leu Leu Glu Gln Arg Arg Gly

1

5

10

40

<210> 44

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

<400> 44

Ala Asn Ser Gln Lys Asp Leu Leu Glu Gln Arg Arg Ala

1

5

10

10

<210> 45

<211> 13

<212> PRT

<213> Artificial Sequence

20

<220>

<223> Description of Artificial Sequence:peptide

<400> 45

Trp Ala Ser Gln Lys Asp Leu Leu Glu Gln Arg Arg Ala

1

5

10

30

<210> 46

<211> 13

<212> PRT

<213> Artificial Sequence

40

<220>

<223> Description of Artificial Sequence:peptide

<400> 46

Trp Asn Ala Gln Lys Asp Leu Leu Glu Gln Arg Arg Ala

1

5

10

<210> 47

<211> 13

10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

20

<400> 47

Trp Asn Ser Ala Lys Asp Leu Leu Glu Gln Arg Arg Ala

1

5

10

<210> 48

30

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

40

<400> 48

Trp Asn Ser Gln Ala Asp Leu Leu Glu Gln Arg Arg Ala

1

5

10

<210> 49

<211> 13

<212> PRT

<213> Artificial Sequence

10

<220>

<223> Description of Artificial Sequence:peptide

<400> 49

Trp Asn Ser Gln Lys Ala Leu Leu Glu Gln Arg Arg Ala

20

1

5

10

<210> 50

<211> 13

<212> PRT

<213> Artificial Sequence

30

<220>

<223> Description of Artificial Sequence:peptide

<400> 50

40

Trp Asn Ser Gln Lys Asp Leu Leu Ala Gln Arg Arg Ala

1

5

10

<210> 51

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

10

<400> 51

Trp Asn Ser Gln Lys Asp Leu Leu Glu Gln Arg Ala Ala

1

5

10

20

<210> 52

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

30

<400> 52

Gly Asp Thr Arg Pro Arg Phe Leu Trp Gln Pro Lys Arg

1

5

10

40

<210> 53

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

<400> 53

Thr Arg Pro Arg Phe Leu Trp Gln Pro Lys Arg Glu Cys

1

5

10

10

<210> 54

<211> 13

<212> PRT

<213> Artificial Sequence

20

<220>

<223> Description of Artificial Sequence:peptide

<400> 54

Pro Arg Phe Leu Trp Gln Pro Lys Arg Glu Cys His Phe

1

5

10

30

<210> 55

<211> 13

<212> PRT

<213> Artificial Sequence

40

<220>

<223> Description of Artificial Sequence:peptide

<400> 55

Phe Leu Trp Gln Pro Lys Arg Glu Cys His Phe Phe Asn

1

5

10

10

<210> 56

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

20

<223> Description of Artificial Sequence:peptide

<400> 56

Trp Gln Pro Lys Arg Glu Cys His Phe Phe Asn Gly Thr

1

5

10

30

<210> 57

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

40

<223> Description of Artificial Sequence:peptide

<400> 57

Pro Lys Arg Glu Cys His Phe Phe Asn Gly Thr Glu Arg

1

5

10

<210> 58

<211> 13

<212> PRT

10

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

<400> 58

20

Arg Glu Cys His Phe Phe Asn Gly Thr Glu Arg Val Arg

1

5

10

<210> 59

<211> 13

<212> PRT

30

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

40

<400> 59

Cys His Phe Phe Asn Gly Thr Glu Arg Val Arg Phe Leu

1

5

10

<210> 60

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

10

<400> 60

Phe Phe Asn Gly Thr Glu Arg Val Arg Phe Leu Asp Arg

1

5

10

20

<210> 61

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

30

<223> Description of Artificial Sequence:peptide

<400> 61

Asn Gly Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe

1

5

10

40

<210> 62

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

<400> 62

10

Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe Tyr Asn

1

5

10

<210> 63

<211> 13

20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

30

<400> 63

Arg Val Arg Phe Leu Asp Arg Tyr Phe Tyr Asn Gln Glu

1

5

10

<210> 64

40

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

<400> 64

Arg Phe Leu Asp Arg Tyr Phe Tyr Asn Gln Glu Glu Ser

1

5

10

10

<210> 65

<211> 13

<212> PRT

<213> Artificial Sequence

20

<220>

<223> Description of Artificial Sequence:peptide

<400> 65

Leu Asp Arg Tyr Phe Tyr Asn Gln Glu Glu Ser Val Arg

1

5

10

30

<210> 66

<211> 13

<212> PRT

<213> Artificial Sequence

40

<220>

<223> Description of Artificial Sequence:peptide

<400> 66

Arg Tyr Phe Tyr Asn Gln Glu Glu Ser Val Arg Phe Asp

1

5

10

<210> 67

<211> 13

10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

20

<400> 67

Phe Tyr Asn Gln Glu Glu Ser Val Arg Phe Asp Ser Asp

1

5

10

<210> 68

30

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

40

<400> 68

Asn Gln Glu Glu Ser Val Arg Phe Asp Ser Asp Val Gly

1

5

10

<210> 69

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

10

<400> 69

Glu Glu Ser Val Arg Phe Asp Ser Asp Val Gly Glu Phe

1

5

10

20

<210> 70

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

30

<400> 70

Ser Val Arg Phe Asp Ser Asp Val Gly Glu Phe Arg Ala

1

5

10

40

<210> 71

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

10

<400> 71

Arg Phe Asp Ser Asp Val Gly Glu Phe Arg Ala Val Thr

1

5

10

<210> 72

20

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

30

<400> 72

Asp Ser Asp Val Gly Glu Phe Arg Ala Val Thr Glu Leu

1

5

10

40

<210> 73

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

<400> 73

Asp Val Gly Glu Phe Arg Ala Val Thr Glu Leu Gly Arg

1

5

10

10

<210> 74

<211> 13

<212> PRT

<213> Artificial Sequence

20

<220>

<223> Description of Artificial Sequence:peptide

<400> 74

Gly Glu Phe Arg Ala Val Thr Glu Leu Gly Arg Pro Asp

1

5

10

30

<210> 75

<211> 13

<212> PRT

<213> Artificial Sequence

40

<220>

<223> Description of Artificial Sequence:peptide

<400> 75

Phe Arg Ala Val Thr Glu Leu Gly Arg Pro Asp Ala Glu

1

5

10

<210> 76

10

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

20

<400> 76

Ala Val Thr Glu Leu Gly Arg Pro Asp Ala Glu Tyr Trp

1

5

10

<210> 77

30

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

40

<400> 77

Thr Glu Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser

1

5

10

<210> 78

<211> 13

<212> PRT

<213> Artificial Sequence

10

<220>

<223> Description of Artificial Sequence:peptide

<400> 78

Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser Gln Lys

20

1

5

10

<210> 79

<211> 13

<212> PRT

<213> Artificial Sequence

30

<220>

<223> Description of Artificial Sequence:peptide

<400> 79

Arg Pro Asp Ala Glu Tyr Trp Asn Ser Gln Lys Asp Ile

40

1

5

10

<210> 80

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

10

<400> 80

Asp Ala Glu Tyr Trp Asn Ser Gln Lys Asp Ile Leu Glu

1

5

10

20

<210> 81

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

30

<400> 81

Glu Tyr Trp Asn Ser Gln Lys Asp Ile Leu Glu Gln Ala

1

5

10

40

<210> 82

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

<400> 82

Trp Asn Ser Gln Lys Asp Ile Leu Glu Gln Ala Arg Ala

10

1

5

10

<210> 83

<211> 13

<212> PRT

20

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

<400> 83

30

Ser Gln Lys Asp Ile Leu Glu Gln Ala Arg Ala Ala Val

1

5

10

<210> 84

<211> 13

<212> PRT

40

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

<400> 84

Lys Asp Ile Leu Glu Gln Ala Arg Ala Ala Val Asp Thr

1

5

10

10

<210> 85

<211> 13

<212> PRT

<213> Artificial Sequence

20

<220>

<223> Description of Artificial Sequence:peptide

<400> 85

Ile Leu Glu Gln Ala Arg Ala Ala Val Asp Thr Tyr Cys

1

5

10

30

<210> 86

<211> 13

<212> PRT

<213> Artificial Sequence

40

<220>

<223> Description of Artificial Sequence:peptide

<400> 86

Glu Gln Ala Arg Ala Ala Val Asp Thr Tyr Cys Arg His

1

5

10

<210> 87

<211> 13

<212> PRT

<213> Artificial Sequence

10

<220>

<223> Description of Artificial Sequence:peptide

<400> 87

Ala Arg Ala Ala Val Asp Thr Tyr Cys Arg His Asn Tyr

1

5

10

20

<210> 88

<211> 13

<212> PRT

<213> Artificial Sequence

30

<220>

<223> Description of Artificial Sequence:peptide

<400> 88

Ala Ala Val Asp Thr Tyr Cys Arg His Asn Tyr Gly Val

1

5

10

40

<210> 89

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

10

<400> 89

Val Asp Thr Tyr Cys Arg His Asn Tyr Gly Val Val Glu

1

5

10

20

<210> 90

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

30

<400> 90

Thr Tyr Cys Arg His Asn Tyr Gly Val Val Glu Ser Phe

1

5

10

40

<210> 91

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

<400> 91

10

Cys Arg His Asn Tyr Gly Val Val Glu Ser Phe Thr Val

1

5

10

<210> 92

<211> 13

20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

30

<400> 92

His Asn Tyr Gly Val Val Glu Ser Phe Thr Val Gln Arg

1

5

10

<210> 93

40

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

<400> 93

Tyr Gly Val Val Glu Ser Phe Thr Val Gln Arg Arg Val

1 5 10

10

<210> 94

<211> 13

<212> PRT

<213> Artificial Sequence

20

<220>

<223> Description of Artificial Sequence:peptide

<400> 94

Val Val Glu Ser Phe Thr Val Gln Arg Arg Val Gln Pro

1 5 10

30

<210> 95

<211> 13

<212> PRT

<213> Artificial Sequence

40

<220>

<223> Description of Artificial Sequence:peptide

<400> 95

Glu Ser Phe Thr Val Gln Arg Arg Val Gln Pro Lys Val

1

5

10

<210> 96

<211> 13

10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

20

<400> 96

Phe Thr Val Gln Arg Arg Val Gln Pro Lys Val Thr Val

1

5

10

<210> 97

30

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

40

<400> 97

Val Gln Arg Arg Val Gln Pro Lys Val Thr Val Tyr Pro

1

5

10

<210> 98

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

10

<400> 98

Arg Arg Val Gln Pro Lys Val Thr Val Tyr Pro Ser Lys

1

5

10

20

<210> 99

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

30

<400> 99

Val Gln Pro Lys Val Thr Val Tyr Pro Ser Lys Thr Gln

1

5

10

40

<210> 100

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

10

<400> 100

Pro Lys Val Thr Val Tyr Pro Ser Lys Thr Gln Pro Leu

1

5

10

<210> 101

20

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

30

<400> 101

Val Thr Val Tyr Pro Ser Lys Thr Gln Pro Leu Gln His

1

5

10

40

<210> 102

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

<400> 102

Val Tyr Pro Ser Lys Thr Gln Pro Leu Gln His His Asn

1

5

10

10

<210> 103

<211> 13

<212> PRT

<213> Artificial Sequence

20

<220>

<223> Description of Artificial Sequence:peptide

<400> 103

Pro Ser Lys Thr Gln Pro Leu Gln His His Asn Leu Leu

1

5

10

30

<210> 104

<211> 13

<212> PRT

<213> Artificial Sequence

40

<220>

<223> Description of Artificial Sequence:peptide

<400> 104

Lys Thr Gln Pro Leu Gln His His Asn Leu Leu Val Cys

1

5

10

<210> 105

10

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

20

<400> 105

Gln Pro Leu Gln His His Asn Leu Leu Val Cys Ser Val

1

5

10

<210> 106

30

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

40

<400> 106

Leu Gln His His Asn Leu Leu Val Cys Ser Val Ser Gly

1

5

10

<210> 107

<211> 13

<212> PRT

<213> Artificial Sequence

10

<220>

<223> Description of Artificial Sequence:peptide

<400> 107

His His Asn Leu Leu Val Cys Ser Val Ser Gly Phe Tyr

20

1

5

10

<210> 108

<211> 13

<212> PRT

<213> Artificial Sequence

30

<220>

<223> Description of Artificial Sequence:peptide

<400> 108

Asn Leu Leu Val Cys Ser Val Ser Gly Phe Tyr Pro Gly

40

1

5

10

<210> 109

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

10

<400> 109

Leu Val Cys Ser Val Ser Gly Phe Tyr Pro Gly Ser Ile

1

5

10

20

<210> 110

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

30

<400> 110

Cys Ser Val Ser Gly Phe Tyr Pro Gly Ser Ile Glu Val

1

5

10

40

<210> 111

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

<400> 111

Val Ser Gly Phe Tyr Pro Gly Ser Ile Glu Val Arg Trp

1

5

10

10

<210> 112

<211> 13

<212> PRT

<213> Artificial Sequence

20

<220>

<223> Description of Artificial Sequence:peptide

<400> 112

Gly Phe Tyr Pro Gly Ser Ile Glu Val Arg Trp Phe Leu

1

5

10

30

<210> 113

<211> 13

<212> PRT

<213> Artificial Sequence

40

<220>

<223> Description of Artificial Sequence:peptide

<400> 113

Tyr Pro Gly Ser Ile Glu Val Arg Trp Phe Leu Asn Gly

1

5

10

10

<210> 114

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

20

<223> Description of Artificial Sequence:peptide

<400> 114

Gly Ser Ile Glu Val Arg Trp Phe Leu Asn Gly Gln Glu

1

5

10

30

<210> 115

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

40

<223> Description of Artificial Sequence:peptide

<400> 115

Ile Glu Val Arg Trp Phe Leu Asn Gly Gln Glu Glu Lys

1

5

10

<210> 116

<211> 13

<212> PRT

10

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

<400> 116

20

Val Arg Trp Phe Leu Asn Gly Gln Glu Glu Lys Ala Gly

1

5

10

<210> 117

<211> 13

30

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

40

<400> 117

Trp Phe Leu Asn Gly Gln Glu Glu Lys Ala Gly Met Val

1

5

10

<210> 118

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

10

<400> 118

Leu Asn Gly Gln Glu Glu Lys Ala Gly Met Val Ser Thr

1

5

10

20

<210> 119

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

30

<400> 119

Gly Gln Glu Glu Lys Ala Gly Met Val Ser Thr Gly Leu

1

5

10

40

<210> 120

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

<400> 120

10

Glu Glu Lys Ala Gly Met Val Ser Thr Gly Leu Ile Gln

1

5

10

<210> 121

<211> 13

20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

30

<400> 121

Lys Ala Gly Met Val Ser Thr Gly Leu Ile Gln Asn Gly

1

5

10

<210> 122

40

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

<400> 122

Gly Met Val Ser Thr Gly Leu Ile Gln Asn Gly Asp Trp

1

5

10

10

<210> 123

<211> 13

<212> PRT

<213> Artificial Sequence

20

<220>

<223> Description of Artificial Sequence:peptide

<400> 123

Val Ser Thr Gly Leu Ile Gln Asn Gly Asp Trp Thr Phe

1

5

10

30

<210> 124

<211> 13

<212> PRT

<213> Artificial Sequence

40

<220>

<223> Description of Artificial Sequence:peptide

<400> 124

Thr Gly Leu Ile Gln Asn Gly Asp Trp Thr Phe Gln Thr

1

5

10

<210> 125

10

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

20

<400> 125

Leu Ile Gln Asn Gly Asp Trp Thr Phe Gln Thr Leu Val

1

5

10

<210> 126

30

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

40

<400> 126

Gln Asn Gly Asp Trp Thr Phe Gln Thr Leu Val Met Leu

1

5

10

<210> 127

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

10

<400> 127

Gly Asp Trp Thr Phe Gln Thr Leu Val Met Leu Glu Thr

1

5

10

20

<210> 128

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

30

<400> 128

Trp Thr Phe Gln Thr Leu Val Met Leu Glu Thr Val Pro

1

5

10

40

<210> 129

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

10

<400> 129

Phe Gln Thr Leu Val Met Leu Glu Thr Val Pro Arg Ser

1

5

10

<210> 130

20

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

30

<400> 130

Thr Leu Val Met Leu Glu Thr Val Pro Arg Ser Gly Glu

1

5

10

40

<210> 131

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

<400> 131

Val Met Leu Glu Thr Val Pro Arg Ser Gly Glu Val Tyr

1

5

10

10

<210> 132

<211> 13

<212> PRT

<213> Artificial Sequence

20

<220>

<223> Description of Artificial Sequence:peptide

<400> 132

Leu Glu Thr Val Pro Arg Ser Gly Glu Val Tyr Thr Cys

1

5

10

30

<210> 133

<211> 13

<212> PRT

<213> Artificial Sequence

40

<220>

<223> Description of Artificial Sequence:peptide

<400> 133

Thr Val Pro Arg Ser Gly Glu Val Tyr Thr Cys Gln Val

1

5

10

<210> 134

<211> 13

10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

20

<400> 134

Pro Arg Ser Gly Glu Val Tyr Thr Cys Gln Val Glu His

1

5

10

<210> 135

30

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

40

<400> 135

Ser Gly Glu Val Tyr Thr Cys Gln Val Glu His Pro Ser

1

5

10

<210> 136

<211> 13

<212> PRT

<213> Artificial Sequence

10

<220>

<223> Description of Artificial Sequence:peptide

<400> 136

Glu Val Tyr Thr Cys Gln Val Glu His Pro Ser Val Thr

20

1

5

10

<210> 137

<211> 13

<212> PRT

<213> Artificial Sequence

30

<220>

<223> Description of Artificial Sequence:peptide

<400> 137

Tyr Thr Cys Gln Val Glu His Pro Ser Val Thr Ser Pro

40

1

5

10

<210> 138

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

10

<400> 138

Cys Gln Val Glu His Pro Ser Val Thr Ser Pro Leu Thr

1

5

10

20

<210> 139

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

30

<400> 139

Val Glu His Pro Ser Val Thr Ser Pro Leu Thr Val Glu

1

5

10

40

<210> 140

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

<400> 140

His Pro Ser Val Thr Ser Pro Leu Thr Val Glu Trp Arg

10

1

5

10

<210> 141

<211> 13

<212> PRT

20

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

<400> 141

30

Ser Val Thr Ser Pro Leu Thr Val Glu Trp Arg Ala Arg

1

5

10

<210> 142

<211> 13

<212> PRT

40

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

<400> 142

Thr Ser Pro Leu Thr Val Glu Trp Arg Ala Arg Ser Glu

1

5

10

10

<210> 143

<211> 13

<212> PRT

<213> Artificial Sequence

20

<220>

<223> Description of Artificial Sequence:peptide

<400> 143

Pro Leu Thr Val Glu Trp Arg Ala Arg Ser Glu Ser Ala

1

5

10

30

<210> 144

<211> 13

<212> PRT

<213> Artificial Sequence

40

<220>

<223> Description of Artificial Sequence:peptide

<400> 144

Thr Val Glu Trp Arg Ala Arg Ser Glu Ser Ala Gln Ser

1

5

10

<210> 145

<211> 13

<212> PRT

10

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:peptide

<400> 145

20

Val Glu Trp Arg Ala Arg Ser Glu Ser Ala Gln Ser Lys

1

5

10

<210> 146

<211> 801

<212> DNA

30

<213> Homo sapiens

<400> 146

atgggtgtgtc tgaagctccc tggaggctcc tgcattgacag cgctgacagt gacactgatg 60
glgctgagct cccactggc ttgtcttggg gacacccgac cagtttccct gtggcagcct 120
aagagggagt gtcatttctt caatgggacg gagegggtgc ggttcctgga cagatacttc 180
tataaccagg aggagtcctg gcgcttcgac agegacgtgg gggagttccg ggcggtgacg 240
gagctggggc ggcctgacgc tgagtactgg aacagccaga aggacatcct ggagcaggcg 300
cgggccgcgg tggacacctt ctgcagacac aactacgggg ttgtggagag cttcacagtg 360

40

cagcggcgag tccaacctaa ggtgactgla tatecttcaa agaccagcc cctgcagcac 420
 cacaaccicc tggctctgctc tctgagtggc tctatccag gcagcatiga agtcaggagg 480
 ttcctgaacg gccaggaaga gaaggctggg atgggtgcc caggcctgat ccagaatgga 540
 gactggacct tccagacctt ggtgatgctg gaaacagttc ctggaagtgg agaggittac 600
 acctgccaag tggagcacc cagcgtgaca agccctctca cagtggaatg gagagcacgg 660
 tctgaatctg cacagagcaa gatgctgagt ggagtcgggg gctttgtgct gggcctgctc 720
 ttccttgggg cgggctggt catctacttc aggaatcaga aaggacactc tggacttcag 780
 ccaacaggat tctgagctg a 801

10

<210> 147

<211> 266

<212> PRT

20

<213> Homo sapiens

<400> 147

Met Val Cys Leu Lys Leu Pro Gly Gly Ser Cys Met Thr Ala Leu Thr
 1 5 10 15

Val Thr Leu Met Val Leu Ser Ser Pro Leu Ala Leu Ser Gly Asp Thr
 20 25 30

30

Arg Pro Arg Phe Leu Trp Gln Pro Lys Arg Glu Cys His Phe Phe Asn
 35 40 45

Gly Thr Glu Arg Val Arg Phe Leu Asp Arg Tyr Phe Tyr Asn Gln Glu
 50 55 60

40

Glu Ser Val Arg Phe Asp Ser Asp Val Gly Glu Phe Arg Ala Val Thr

65

70

75

80

Glu Leu Gly Arg Pro Asp Ala Glu Tyr Trp Asn Ser Gln Lys Asp Ile

85

90

95

Leu Glu Gln Ala Arg Ala Ala Val Asp Thr Tyr Cys Arg His Asn Tyr

100

105

110

10

Gly Val Val Glu Ser Phe Thr Val Gln Arg Arg Val Gln Pro Lys Val

115

120

125

Thr Val Tyr Pro Ser Lys Thr Gln Pro Leu Gln His His Asn Leu Leu

130

135

140

20

Val Cys Ser Val Ser Gly Phe Tyr Pro Gly Ser Ile Glu Val Arg Trp

145

150

155

160

Phe Leu Asn Gly Gln Glu Glu Lys Ala Gly Met Val Ser Thr Gly Leu

165

170

175

30

Ile Gln Asn Gly Asp Trp Thr Phe Gln Thr Leu Val Met Leu Glu Thr

180

185

190

Val Pro Arg Ser Gly Glu Val Tyr Thr Cys Gln Val Glu His Pro Ser

195

200

205

40

Val Thr Ser Pro Leu Thr Val Glu Trp Arg Ala Arg Ser Glu Ser Ala

210

215

220

240

255

265


10

20

30


□ □ □ □

図 1




□ □ □ □ □

図 2 B




□ □ □ □ □

図 2 A




□ □ □ □ □

図 3 A




□ □ □ □ □

図 3 B




□ □ □ □ □

図 3 D




□ □ □ □ □

図 3 C



□ □ □ □ □


図 4 A



□ □ □ □ □

図 4B


投与用量: 1.0 μ g/head



□ □ □ □ □

図 5A


HD4



□ □ □ □ □

図 5B


HD6



□ □ □ □ □

図 5C

HD8



□ □ □ □

図 6

配列番号	61	62	63	64	65	66	67	68	69	70	71	72	73	HD4	HD6	HD8
24	W	N	S	Q	K	D	F	L	E	D	R	R	A	++++	+++	+++
25	W	N	S	Q	K	D	F	L	E	D	R	R	A	++	++++	++++
26	W	N	S	Q	K	D	F	L	E	D	R	R	A	++++	-	+++
27	W	N	S	Q	K	D	F	L	E	Q	A	R	A	++++	++	++++
28	W	N	S	Q	K	D	I	L	E	D	R	R	A	+++	-	++++
29	W	N	S	Q	K	D	I	L	E	Q	K	R	G	+/-	+	++++
30	W	N	S	Q	K	D	I	L	E	D	R	R	A	+	+/-	++++
31	W	N	S	Q	K	D	I	L	E	D	R	R	G	+/-	-	++++
32	W	N	S	Q	K	D	I	L	E	D	K	R	A	+/-	-	++++
33	W	N	S	Q	K	D	I	L	E	Q	A	R	A	+++	+/-	++++
34	W	N	S	Q	K	D	L	L	E	Q	R	R	A	++	+++	++++
35	W	N	S	Q	K	D	L	L	E	Q	A	R	A	++++	-	++++
36	W	N	S	Q	K	D	L	L	E	Q	K	R	G	+	+	+++
37	W	N	S	Q	K	D	L	L	E	D	R	R	A	+++	+/-	++++
38	W	N	S	Q	K	D	L	L	E	R	R	R	A	++	++++	++++
39	W	N	S	Q	K	D	L	L	E	D	E	R	A	+++	-	+++
40	W	N	S	Q	K	D	A	L	E	Q	R	R	A	+	+++	++++
41	W	N	S	Q	K	D	L	L	E	A	N	R	A	++++	++++	++++
42	W	N	S	Q	K	D	L	L	E	Q	A	R	A	+++	++	++++
43	W	N	S	Q	K	D	L	L	E	Q	R	R	G	+	+++	+++
48	W	N	S	Q	A	D	L	L	E	Q	R	R	A	-	+/-	+/-
49	W	N	S	Q	K	A	L	L	E	Q	R	R	A	-	++	+/-
50	W	N	S	Q	K	D	L	L	A	Q	R	R	A	-	++	-
51	W	N	S	Q	K	D	L	L	E	Q	R	A	A	-	+/-	-
44	A	N	S	Q	K	D	L	L	E	Q	R	R	A	+/-	+++	++++
45	W	A	S	Q	K	D	L	L	E	Q	R	R	A	+	++	++++
46	W	N	A	Q	K	D	L	L	E	Q	R	R	A	+	++	++++
47	W	N	S	A	K	D	L	L	E	Q	R	R	A	+	++	++++

□ □ □ □ □ □ □ □

INTERNATIONAL SEARCH REPORT		International application No. PCT/JP02/10665
A. CLASSIFICATION OF SUBJECT MATTER Int.Cl. ⁷ C07K16/28, C12N5/10, C12N15/13, C12N1/21, C12N1/19, C12P21/08, A61K39/395 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Int.Cl. ⁷ C07K16/28, C12N5/10, C12N15/13, C12N1/21, C12N1/19, C12P21/08, A61K39/395 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) REGISTRY (STN), CA (STN), MEDLINE (STN), WPI (DIALOG), BIOSIS (DIALOG), GenBank/EMBL/DBJ/GenSeq, SwissProt/PIR/GenSeq		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KOSTELNY, S.A. et al., Humanization and characterization of the anti-HLA-DR antibody 1D10. Int. J. Cancer 2001. Aug, Vol.93, No.4, pages 556 to 565	1-93
Y	NIMAN, H.L. et al., Generation of protein-reactive antibodies by short peptides is an event of high frequency; implications for the structural basis of immune recognition. Proc. Natl. Acad. Sci. USA. 1983, Vol.80, No.16, pages 4949 to 4953	1-93
Y	ULRICH, R.G. et al., Immune recognition of human major histocompatibility antigens: localization by a comprehensive synthetic strategy of the continuous antigenic sites in the first domain of HLA-DR2 β chain. Eur. J. Immunol. 1987, Vol.17, No.4, pages 497 to 502	1-93
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "C" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 16 January, 2003 (16.01.03)		Date of mailing of the international search report 28 January, 2003 (28.01.03)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

国際調査報告		国際出版番号 PCT/J P 0 2 / 1 0 6 6 5
A. 発明の属する分野の分類 (国際特許分類 (IPC))		
Int. Cl ⁷ C07K 16/28, C12N 5/10, C12N 15/13, C12N 1/21, C12N 1/19, C12P 21/08, A61K 39/395		
B. 調査を行った分野		
調査を行った最小限資料 (国際特許分類 (IPC))		
Int. Cl ⁷ C07K 16/28, C12N 5/10, C12N 15/13, C12N 1/21, C12N 1/19, C12P 21/08, A61K 39/395		
最小限資料以外の資料で調査を行った分野に含まれるもの		
国際調査で使用した電子データベース (データベースの名称、調査に使用した用語)		
REGISTRY (STN), CA (STN), MEDLINE (STN), WPI (DIALOG), BIOSIS (DIALOG), GenBank/EMBL/DDBJ/GenSeq, SwissProt/PIR/GenSeq		
C. 関連すると認められる文献		
引用文献の カテゴリー*	引用文献名 及び一部の箇所が関連するときは、その関連する箇所の表示	関連する 請求の範囲の番号
Y	KOSTELNY, S. A. et al. Humanization and characterization of the anti-HLA-DR antibody 1D10. Int. J. Cancer 2001. Aug, Vol. 93, No. 4, p. 556-565	1-93
Y	NIMAN, H. L. et al. Generation of protein-reactive antibodies by short peptides is an event of high frequency: implications for the structural basis of immune recognition. Proc. Natl. Acad. Sci. USA. 1983, Vol. 80, No. 16, p. 4949-4953	1-93
<input checked="" type="checkbox"/> C欄の続きにも文献が列挙されている。 <input type="checkbox"/> パテントファミリーに関する別紙を参照。		
* 引用文献のカテゴリー 「A」 特に関連のある文献ではなく、一般的技術水準を示すもの 「E」 国際出願日前の出願または特許であるが、国際出願日以後に公表されたもの 「L」 優先権主張に疑義を提起する文献又は他の文献の発行日若しくは他の特別な理由を確立するために引用する文献 (理由を付す) 「O」 口頭による開示、使用、展示等に言及する文献 「P」 国際出願日前で、かつ優先権の主張の基礎となる出願		
の日の後に公表された文献 「T」 国際出願日又は優先日後に公表された文献であって出願と矛盾するものではなく、発明の原理又は理論の理解のために引用するもの 「X」 特に関連のある文献であって、当該文献のみで発明の新規性又は進歩性がないと考えられるもの 「Y」 特に関連のある文献であって、当該文献と他の1以上の文献との、当業者にとって自明である組合せによって進歩性がないと考えられるもの 「&」 同一パテントファミリー文献		
国際調査を完了した日	1 6 . 0 1 . 0 3	国際調査報告の発送日
国際調査機関の名称及びあて先	日本国特許庁 (ISA/J P) 郵便番号 100-8915 東京都千代田区霞が関三丁目4番3号	特許庁審査官 (権限のある職員) 高須 栄二
		4 B 9 2 8 1
		電話番号 03-3581-1101 内線 3448

国際調査報告		国際出願番号 PCT/J P 02/10665
C (続き) . 関連すると認められる文献		
引用文献の カテゴリー*	引用文献名 及び一部の箇所が関連するときは、その関連する箇所の表示	関連する 請求の範囲の番号
Y	ULRICH, R. G. et al. Immune recognition of human major histocompatibility antigens: localization by a comprehensive synthetic strategy of the continuous antigenic sites in the first domain of HLA-DR2 β chain. Eur. J. Immunol. 1987, Vol. 17, No. 4, p. 497-502	1-93

[illegible]